16 / 27
Trabectedin in OVA-301 PPS Stratum (PFI = 6–12 mo)
Overall survival
in partially platinum-sensitive patients who received
treatment with
platinum as first-subsequent third-line treatment
Added to its own activity,
trabectedin + PLD extends PFI, allowing the next platinum
treatment to be more active and providing extra time for patients to recover from
previous toxicities
Poveda A, et al. Cancer Treat Rev. 2014;40(3):366-375.